Fulgent Genetics, Inc.

NasdaqGM:FLGT 株式レポート

時価総額:US$601.5m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Fulgent Genetics 過去の業績

過去 基準チェック /06

Fulgent Geneticsの収益は年間平均-5%の割合で減少していますが、 Healthcare業界の収益は年間 増加しています。収益は年間5.6% 21.7%割合で 増加しています。

主要情報

-5.0%

収益成長率

-5.8%

EPS成長率

Healthcare 業界の成長8.5%
収益成長率21.7%
株主資本利益率-15.4%
ネット・マージン-57.7%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Jan 25
Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy

Jan 09

Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot

Dec 20

収支内訳

Fulgent Genetics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:FLGT 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 24288-16612643
31 Dec 23289-16812841
30 Sep 23286-6411338
30 Jun 23307-4913235
31 Mar 23365-2614233
31 Dec 2261914314429
30 Sep 2280327214128
30 Jun 2292539211826
31 Mar 229534619625
31 Dec 219935077524
30 Sep 211,0365695821
30 Jun 219104934818
31 Mar 217734174015
31 Dec 204222143012
30 Sep 2013548219
30 Jun 20443157
31 Mar 20350137
31 Dec 19330127
30 Sep 1930-2116
30 Jun 1925-4116
31 Mar 1922-6106
31 Dec 1821-6106
30 Sep 1820-5105
30 Jun 1819-6105
31 Mar 1818-5105
31 Dec 1719-394
30 Sep 1720094
30 Jun 1721-584
31 Mar 1720-1374
31 Dec 1618-1474
30 Sep 1615-2296
30 Jun 1613-1575
31 Mar 1611-675
31 Dec 1510-554
31 Dec 141-111

質の高い収益: FLGTは現在利益が出ていません。

利益率の向上: FLGTは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: FLGTは利益が出ておらず、過去 5 年間で損失は年間5%の割合で増加しています。

成長の加速: FLGTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: FLGTは利益が出ていないため、過去 1 年間の収益成長をHealthcare業界 ( 15.1% ) と比較することは困難です。


株主資本利益率

高いROE: FLGTは現在利益が出ていないため、自己資本利益率 ( -15.38% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘